Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus bevacizumab as adjuvant therapy in HCC
NCT04682210Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04682210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682210.